Chris Richard
Fortune : 561 938 $ au 30/09/2026
Fortune : 561 938 $ au 30/09/2026
Christian M.
Richard is currently Director at Amphivena Therapeutics, Inc. and Rainier Therapeutics, Inc. Mr. Richard serves as Independent Director at Cypherpunk Technologies, Inc. since 2023.
Mr. Richard is Portfolio Manager at Monashee Investment Management LLC starting in 2024.
Formerly, Mr. Richard was Senior Vice President of Research at Tekla Capital Management LLC from 2015 to 2020.
Mr. Richard was Partner & Head of Research at Merlin Nexus from 2004 to 2015.
Mr. Richard worked as Associate Research Scientist at Schering-Plough Research Institute from 1997 to 2001.
Mr. Richard completed graduate and Masters of Business Administration degrees at New York University.
Mr. Richard earned an undergraduate degree from Purchase College in 1993.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/07/2026 | 168 750 ( 0,16% ) | 561 938 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. | Directeur/Membre du Conseil | 17/01/2023 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Directeur/Membre du Conseil | - |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. BiotechnologyHealth Technology Develops clinical-stage immuno-oncology therapeutics | Directeur/Membre du Conseil | - |
Monashee Investment Management LLC
Monashee Investment Management LLC Investment ManagersFinance Monashee seeks to provide consistently stronger returns than the broader equity markets by investing systematically in the equity and convertible debt securities of companies raising new equity capital globally or via secondary offerings, block trades, registered direct offerings and PIPEs where a significant shareholder seeks to sell a secondary position. The firm will seek to capture the discount inherent in equity new issues, including both offerings by companies that are already publicly traded (follow-ons) and initial public offerings (IPOs). | Gestionnaire de Portefeuille-Actions | 01/09/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Analyst-Equity | 01/11/2020 |
Merlin Nexus
Merlin Nexus Investment ManagersFinance Merlin Nexus invests in both private and public life sciences companies across the globe. The firm focuses on sectors such as biotechnology, medical devices, molecular diagnostics, and specialty pharmaceuticals. It participates in late-stage and PIPE (Private Investments in Public Equity) transactions. | Analyste en capital-investissement | 28/02/2015 |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research | Corporate Officer/Principal | 31/12/2001 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 9 |
|---|---|
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Finance |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merlin Nexus
Merlin Nexus Investment ManagersFinance Merlin Nexus invests in both private and public life sciences companies across the globe. The firm focuses on sectors such as biotechnology, medical devices, molecular diagnostics, and specialty pharmaceuticals. It participates in late-stage and PIPE (Private Investments in Public Equity) transactions. | Finance |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research | Health Technology |
Purchase College
Purchase College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monashee Investment Management LLC
Monashee Investment Management LLC Investment ManagersFinance Monashee seeks to provide consistently stronger returns than the broader equity markets by investing systematically in the equity and convertible debt securities of companies raising new equity capital globally or via secondary offerings, block trades, registered direct offerings and PIPEs where a significant shareholder seeks to sell a secondary position. The firm will seek to capture the discount inherent in equity new issues, including both offerings by companies that are already publicly traded (follow-ons) and initial public offerings (IPOs). | Finance |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. BiotechnologyHealth Technology Develops clinical-stage immuno-oncology therapeutics | Health Technology |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Health Technology |
Leap Therapeutics, Inc.
Leap Therapeutics, Inc. Financial ConglomeratesFinance Operates as a digital asset treasury company | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national